Welcome to our dedicated page for ZYNEX news (Ticker: $ZYXI), a resource for investors and traders seeking the latest updates and insights on ZYNEX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZYNEX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZYNEX's position in the market.
Zynex, Inc. (NASDAQ: ZYXI) has announced that two of its executives, Anna Lucsok, Chief Operating Officer, and Steve Fox, Vice President of Sales, have been recognized among the Top 25 Medical Device Executives by The Healthcare Technology Report. This recognition showcases the high caliber of talent within Zynex, emphasizing their expertise in managing product portfolios and leading departments.
Zynex, Inc. (NASDAQ: ZYXI) reported Q1 2024 revenue of $46.5 million, a 10% increase. Despite revenue underperformance due to delayed payments from insurers post a cyber incident, Zynex remains confident in its full-year revenue forecast. The company saw a net income of $10,000 and repurchased $13.4 million of common stock. New FDA approvals, product launches, and revenue diversification through therapy products show promising growth prospects for Zynex in 2024.
